Last updated: October 1, 2026
Taltz, Eli Lilly’s ixekizumab, generated approximately $3.0 billion in 2024 sales, up from $2.0 billion in 2021. Its growth has been supported by expansion across plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and pediatric indications. The principal commercial risks are biologic competition from IL-17 and IL-23 inhibitors, increasing use of oral immunomodulators, and future biosimilar entry after the U.S. biologic exclusivity period.
Taltz remains a major immunology asset, but its growth rate is moderating as the market shifts toward newer IL-23 therapies, including Skyrizi and Tremfya, and oral agents such as Rinvoq and Bimzelx. No U.S. ixekizumab biosimilar has been approved, and the product retains a substantial commercial window before biosimilar substitution becomes a material threat.
How much revenue does Taltz generate?
Taltz revenue has increased consistently since launch. Eli Lilly reports product revenue by brand, with sales growth driven by U.S. demand, international expansion, label additions, and increased use in rheumatology.
| Fiscal year |
Taltz revenue |
Approximate year-over-year growth |
| 2021 |
$2.04 billion |
18% |
| 2022 |
$2.48 billion |
21% |
| 2023 |
$2.75 billion |
11% |
| 2024 |
Approximately $3.0 billion |
Approximately 10% |
Sources: Eli Lilly annual reports and financial disclosures.[1-4]
From 2021 through 2024, Taltz revenue grew at an estimated compound annual growth rate of approximately 14%. The trajectory is favorable, but the annual growth rate has declined from the high teens to roughly 10% as the product approaches maturity in psoriasis and faces more intense competition in inflammatory disease.
Taltz is one of Lilly’s largest established growth products, although its financial importance is now lower relative to Mounjaro, Zepbound, and other incretin products. Lilly’s 2024 results show that Taltz remains material to the company’s immunology portfolio, but it is no longer the primary driver of corporate revenue growth.
What diseases and patient populations does Taltz treat?
Taltz is a monoclonal antibody that selectively inhibits interleukin-17A, a cytokine involved in inflammatory skin and musculoskeletal diseases.
FDA-approved indications
The FDA has approved Taltz for:
- Moderate-to-severe plaque psoriasis in adults and pediatric patients aged 6 years and older who are candidates for systemic therapy or phototherapy.
- Active psoriatic arthritis in adults.
- Active ankylosing spondylitis in adults.
- Non-radiographic axial spondyloarthritis with objective signs of inflammation in adults.
- Certain pediatric psoriasis populations.
The FDA initially approved Taltz in March 2016 for moderate-to-severe plaque psoriasis. Subsequent label expansions added psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric use.[5]
The broad indication set gives Taltz access to dermatology, rheumatology, and pediatric specialty markets. That diversification reduces dependence on plaque psoriasis alone. It also exposes the product to different competitive dynamics. Dermatology is increasingly dominated by IL-23 inhibitors, while rheumatology has significant competition from TNF inhibitors, JAK inhibitors, IL-17 inhibitors, and IL-6 therapies.
How does Taltz compare with competing biologic drugs?
Taltz competes primarily with biologics and targeted synthetic drugs used in psoriasis, psoriatic arthritis, and axial spondyloarthritis.
| Product |
Active ingredient |
Primary mechanism |
Manufacturer |
Main competitive position |
| Taltz |
Ixekizumab |
IL-17A inhibitor |
Eli Lilly |
Strong psoriasis and axial spondyloarthritis presence |
| Cosentyx |
Secukinumab |
IL-17A inhibitor |
Novartis |
Broad IL-17 franchise and long commercial history |
| Skyrizi |
Risankizumab |
IL-23 inhibitor |
AbbVie |
Strong psoriasis and psoriatic arthritis growth |
| Tremfya |
Guselkumab |
IL-23 inhibitor |
Johnson & Johnson |
Dermatology and rheumatology expansion |
| Bimzelx |
Bimekizumab |
IL-17A and IL-17F inhibitor |
UCB |
Newer high-efficacy IL-17 competitor |
| Humira |
Adalimumab |
TNF inhibitor |
AbbVie and biosimilar manufacturers |
Large installed base, but exposed to biosimilar erosion |
| Rinvoq |
Upadacitinib |
JAK inhibitor |
AbbVie |
Oral option across inflammatory diseases |
| Sotyktu |
Deucravacitinib |
TYK2 inhibitor |
Bristol Myers Squibb |
Oral psoriasis competitor |
Taltz versus IL-23 inhibitors
IL-23 inhibitors have become the most important threat to Taltz in plaque psoriasis. Their dosing schedules are generally less frequent than Taltz, which can improve convenience and persistence. Skyrizi and Tremfya also have expanding indications, increasing their ability to compete in both dermatology and rheumatology.
Taltz retains advantages in axial spondyloarthritis, where IL-17 biology is well established and the product has a broad label. IL-23 inhibitors have not displaced IL-17 therapy across all axial disease segments.
Taltz versus Cosentyx
Cosentyx is Taltz’s closest mechanistic competitor. Both inhibit IL-17A and have psoriasis, psoriatic arthritis, and axial spondyloarthritis indications. Novartis has a longer commercial lead, while Lilly has used clinical data, patient support, and rheumatology expansion to defend Taltz share.
Competitive differentiation is based less on mechanism than on dosing, payer access, physician familiarity, formulary position, safety perception, and patient persistence.
Taltz versus Bimzelx
Bimzelx inhibits both IL-17A and IL-17F and has entered the U.S. psoriasis market as a higher-efficacy biologic competitor. Its commercial effect on Taltz will depend on market access, long-term safety, dosing convenience, and uptake among patients inadequately controlled on existing IL-17 therapies.
When does Taltz lose U.S. biologic exclusivity?
Taltz received FDA approval on March 22, 2016. The U.S. Biologics Price Competition and Innovation Act provides a reference biologic with 12 years of statutory exclusivity from the date of first licensure. On that basis, the principal U.S. reference-product exclusivity period runs to March 22, 2028.[5-7]
This date does not automatically establish the first possible commercial launch of an ixekizumab biosimilar. A biosimilar applicant must complete the FDA approval process, satisfy applicable patent obligations, and resolve or manage patent litigation. A biosimilar could be approved after the exclusivity period but still face a later launch date if patents remain enforceable.
U.S. exclusivity timeline
| Event |
Date |
| Initial FDA approval |
March 22, 2016 |
| Twelve-year reference biologic exclusivity |
March 22, 2028 |
| Likely period for heightened biosimilar activity |
2026-2028 |
| Commercial biosimilar risk |
Late 2020s onward, depending on patent outcomes |
The commercial significance of 2028 is different from the significance of patent expiration. Regulatory exclusivity blocks FDA approval of a biosimilar for a defined period. Patent rights can delay launch beyond that date, but only if the relevant claims are valid, enforceable, and infringed.
What patents protect Taltz?
Taltz is protected by a portfolio covering ixekizumab antibodies, antibody-binding characteristics, therapeutic use, formulations, manufacturing, and related biologic processes. The precise enforceable estate depends on patent-family members, terminal disclaimers, patent-term adjustment, patent-term extension, claim scope, and jurisdiction.
A representative foundational U.S. patent family associated with anti-IL-17A antibodies includes U.S. Patent No. 8,110,197. The relevant patent family has roots in applications filed before Taltz’s commercial launch and generally reaches into the late 2020s, subject to the specific patent term and any applicable adjustments.[8]
What formulations are protected by Taltz patents?
Formulation protection for monoclonal antibodies can cover:
- Concentrated liquid formulations.
- Stabilized antibody compositions.
- Subcutaneous delivery presentations.
- Excipients and pH ranges.
- Prefilled syringes and autoinjector configurations.
- Storage and administration characteristics.
Formulation claims can create practical barriers even when composition-of-matter claims approach expiration. Their value depends on whether a biosimilar can design around the claims without sacrificing stability, concentration, usability, or manufacturing economics.
What method-of-use patents protect Taltz?
Method-of-use protection can cover treatment of:
- Plaque psoriasis.
- Psoriatic arthritis.
- Ankylosing spondylitis.
- Non-radiographic axial spondyloarthritis.
- Pediatric inflammatory disease populations.
- Specific dosing regimens or patient subgroups.
Method-of-use patents are less effective against a biosimilar approved for an unpatented indication if the applicant uses a skinny-label strategy. They remain relevant when the patented indication is commercially important, when prescribing cannot be cleanly separated by disease, or when the patent claims cover a core dosing regimen.
What is the Orange Book status of Taltz?
Taltz is not listed in the FDA Orange Book because it is a biologic rather than a conventional small-molecule drug. Biologic reference products and biosimilars are tracked through the FDA Purple Book.[6]
The Orange Book framework does not provide the same public patent-listing structure for Taltz that exists for small-molecule products such as Humira’s predecessor small-molecule analogs or oral immunology drugs. For Taltz, patent analysis requires review of issued patents, patent-family records, FDA exclusivity information, litigation filings, and biosimilar disclosure activity.
Are there Paragraph IV challenges to Taltz?
Paragraph IV certifications apply to abbreviated new drug applications for small-molecule drugs under the Hatch-Waxman Act. Taltz is a biologic, so a conventional Paragraph IV challenge is not the applicable pathway.
A future ixekizumab biosimilar applicant would proceed under the BPCIA, not through an ANDA Paragraph IV certification. The BPCIA process includes patent-information exchange, the statutory patent dance, potential infringement litigation, and negotiated or court-determined launch arrangements.[7]
As of the latest available public information, no ixekizumab biosimilar has created a U.S. launch event comparable to the major adalimumab biosimilar disputes. The absence of a public biosimilar launch does not eliminate future risk, but it indicates that immediate erosion is limited.
Which companies are challenging Taltz commercially?
Taltz faces competition from several groups of manufacturers.
Direct IL-17 competitors
Novartis competes through Cosentyx, while UCB competes through Bimzelx. These products have similar or overlapping use in psoriasis and psoriatic arthritis. Cosentyx has established physician adoption and a broad inflammatory-disease franchise. Bimzelx is newer and competes on dual IL-17A/IL-17F inhibition and efficacy.
IL-23 competitors
AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya are the most important class-level threats in plaque psoriasis. Their longer dosing intervals and expanding labels support payer and physician adoption.
Oral targeted therapies
AbbVie’s Rinvoq, Bristol Myers Squibb’s Sotyktu, and other oral agents compete against injectable biologics. Oral treatment can be attractive to patients who prioritize administration convenience, although safety warnings and payer restrictions influence use.
Biosimilar competitors
The most credible long-term biosimilar threat would come from large pharmaceutical or specialty manufacturers with biologic development, manufacturing, and commercialization capabilities. No approved U.S. ixekizumab biosimilar has established a current competitive benchmark.
What is the litigation status of Taltz?
Taltz has not generated a publicly visible U.S. patent litigation cycle comparable to Humira, Stelara, or major oncology biologics. The principal future litigation risk would arise from a BPCIA patent dispute involving a biosimilar applicant.
Potential litigation issues include:
- Validity of anti-IL-17A antibody claims.
- Infringement of formulation or dosing patents.
- Patent exhaustion and manufacturing claims.
- Biosimilar interchangeability-related issues.
- Skinny-label prescribing and induced infringement.
- Patent-term calculations and terminal disclaimers.
The absence of a major public litigation event reduces near-term launch uncertainty but does not establish that the entire Taltz estate is weak. Patent strength must be assessed claim by claim.
How strong is the Taltz patent estate?
Taltz has a moderate-to-strong commercial protection profile through the late 2020s, based on four factors:
- The product has an established biologic exclusivity period through 2028.
- The core antibody and related patent families extend into the late 2020s.
- Taltz has multiple indications, creating potential method-of-use protection.
- Subcutaneous formulations and delivery presentations can create additional design-around costs.
The estate is not immune to biosimilar competition. Antibody patents can face validity challenges, and a biosimilar manufacturer may avoid selected method-of-use claims. Formulation patents also have narrower practical value if an alternative formulation can be developed.
The strongest protection is likely to come from overlapping core antibody, formulation, and manufacturing rights rather than from any single method-of-use patent.
What generic or biosimilar launch scenarios exist for Taltz?
Scenario 1: No launch before 2028
This is the base case for near-term revenue planning. Taltz continues to grow modestly through 2026 and 2027, supported by label breadth and the absence of direct biosimilar substitution.
Scenario 2: Biosimilar approval with delayed commercial launch
A biosimilar could obtain FDA approval after the statutory exclusivity period but launch later because of patent litigation or a negotiated settlement. This would create limited immediate revenue erosion but increase payer pressure.
Scenario 3: First biosimilar launch in the late 2020s
A first entrant could trigger rapid net-price reductions, particularly in psoriasis, where payers can move patients across several biologic classes. The initial erosion would likely be slower than for small molecules because biologic substitution is governed by interchangeability, payer contracts, and prescriber behavior.
Scenario 4: Multiple biosimilars after 2030
Several entrants would create the greatest price pressure. The impact would depend on interchangeability designations, pharmacy benefit coverage, specialty-distribution contracts, and the number of competing IL-17 and IL-23 products available at the same time.
What is the geographic coverage of Taltz?
Taltz is marketed in the United States and major international markets, including Europe and Japan, subject to country-specific approvals and reimbursement. International sales generally carry lower net pricing than U.S. sales and are more exposed to health-technology assessment requirements, tendering, and national reimbursement controls.
The United States remains the most important market for revenue and margin. Europe has strategic value because of the size of the psoriasis and rheumatology populations, but pricing pressure is structurally greater.
What manufacturing and intellectual-property barriers protect Taltz?
Taltz manufacturing requires mammalian-cell expression, purification, viral clearance, analytical characterization, and sterile injectable production. These requirements create technical and capital barriers for biosimilar developers.
The principal manufacturing barriers include:
- Cell-line and process development.
- Control of glycosylation and product-related impurities.
- Demonstration of analytical similarity.
- Scale-up and process consistency.
- Stability and container-closure validation.
- Regulatory comparability studies.
- Specialty injectable distribution.
Manufacturing complexity supports continued brand pricing, but it does not prevent biosimilar entry. Experienced biologics manufacturers can overcome these barriers, especially when the reference product has a large revenue base.
How does Taltz’s financial trajectory compare with its patent risk?
Taltz has a favorable medium-term financial profile. Revenue is still growing, and the product has a diversified indication base. The main financial risk is not an immediate patent cliff. It is gradual share and price erosion caused by newer therapies before biosimilar entry.
A reasonable commercial framework is:
| Period |
Expected market condition |
| 2025-2026 |
Continued growth, with increasing IL-23 and Bimzelx competition |
| 2027 |
Mature-brand phase; payer pressure likely increases |
| 2028 |
Regulatory exclusivity ends; biosimilar activity becomes more relevant |
| 2029-2030 |
Potential first-wave biosimilar and net-price pressure |
| After 2030 |
Greater erosion risk if multiple biosimilars launch |
Taltz’s revenue durability will depend on Lilly’s ability to maintain formulary access, retain patients in rheumatology, expand pediatric and axial disease use, and defend the product against newer dosing and efficacy profiles.
Key Takeaways
- Taltz revenue rose from approximately $2.04 billion in 2021 to about $3.0 billion in 2024.
- The product has a broad FDA label across psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.
- U.S. biologic exclusivity runs to March 2028 based on the March 22, 2016 approval date.
- Taltz is tracked in the FDA Purple Book, not the Orange Book.
- Paragraph IV challenges do not apply; future challenges would proceed under the BPCIA biosimilar framework.
- The principal commercial threats are Skyrizi, Tremfya, Cosentyx, Bimzelx, Rinvoq, and other targeted immunology products.
- No U.S. ixekizumab biosimilar has created a current commercial launch event.
- The late-2020s represent the key transition period from branded growth to biosimilar and price-erosion risk.
- Taltz has a meaningful patent estate, but its strength depends on claim scope, patent term, formulation coverage, and litigation outcomes.
FAQs About Taltz Market and Patent Risk
Does Taltz have a biosimilar?
No U.S.-approved ixekizumab biosimilar has established commercial competition as of the latest available public information. Biosimilar activity is more likely to become material after the 2028 reference-product exclusivity period.
Is Taltz interchangeable with Cosentyx?
No. Taltz and Cosentyx are separate biologic products containing different active antibodies. Both inhibit IL-17A, but they require separate prescribing and payer authorization.
Will Taltz lose exclusivity in 2028?
The 12-year U.S. reference biologic exclusivity period is expected to end in March 2028. Patent rights may delay commercial biosimilar entry beyond that date.
Which indication is most important to Taltz revenue?
Plaque psoriasis has historically been the core indication, but rheumatology and axial spondyloarthritis have become important sources of diversification and retention.
Is Taltz at risk from oral psoriasis drugs?
Yes. Oral therapies such as TYK2 and JAK inhibitors can compete for patients who prefer noninjectable treatment. Their uptake is moderated by safety labeling, payer controls, and disease-specific prescribing practices.
References
- Eli Lilly and Company. (2022). 2021 annual report.
- Eli Lilly and Company. (2023). 2022 annual report.
- Eli Lilly and Company. (2024). 2023 annual report.
- Eli Lilly and Company. (2025). 2024 annual report.
- U.S. Food and Drug Administration. (2016). FDA approves new treatment for moderate-to-severe plaque psoriasis.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- Biologics Price Competition and Innovation Act of 2009, 42 U.S.C. § 262.
- U.S. Patent and Trademark Office. (n.d.). U.S. Patent No. 8,110,197, anti-IL-17A antibodies.
